Mechanismen van resistentie tegen EGFR/HER2-antilichamen

J. Aleman, A. D.R. Huitema, J. H.M. Schellens, J. H. Beijnen

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review


Monoclonal antibodies against the epidermal growth factor receptors EGFR and HER2 constitute an important advance in the treatment of breast cancer, metastatic colorectal cancer and head and neck tumours. However, resistance against these drugs may occur. The molecular mechanisms of resistance can be attributed to several processes. Extracellular, mutated receptors in the bloodstream may compete with transmembrane receptors. At receptor level ECFR and HER2 can be influenced by, among others, tyrosine kinase receptors such as the insulin-like growth factor 1R. At the intracellular level there can be specific mutations or other mechanisms resulting in a continuous activation of the downstream cascade. Specific biomarkers exist to predict the effect of a therapy with monoclonal antibodies, although these are not conclusive. New markers are (urgently) needed in the future. New therapies to circumvent resistance are being investigated at present.

Vertaalde titel van de bijdrageMechanisms of resistance against EGFR/HER2 antibodies
Originele taal-2Nederlands
Pagina's (van-tot)172-177
Aantal pagina's6
TijdschriftPharmaceutisch Weekblad
Nummer van het tijdschrift42
StatusGepubliceerd - okt. 2009
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Mechanismen van resistentie tegen EGFR/HER2-antilichamen'. Samen vormen ze een unieke vingerafdruk.

Citeer dit